Inhibiting aurora kinases has shown promise in preclinical and clinical trials for solid tumors, including HNSCC.39, 40, 41, 42 In terms of potential clinical application, using aurora kinase inhibitors to suppress cancer cell proliferation may be a feasible strategy for mimicking EMILIN-1 overexpression in HNSCC. This evidence concerns the gene EMILIN1 and head and neck squamous cell carcinoma.